• Alterity Therapeutics presented new analyses from its Phase 2 ATH434-201 trial in multiple system atrophy during a Late Breaking Science session at American Academy of Neurology annual meeting.
• Analyses indicated ATH434 slowed functional decline versus placebo on a newly developed composite scale designed to better track disease progression.
• Results also supported previously reported benefits across daily function and neurological assessment, reinforcing ATH434’s disease-modifying profile.
• Update positions Alterity to move toward Phase 3 discussions with regulators.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-012959), on April 22, 2026, and is solely responsible for the information contained therein.